April 20th, 2015
This week’s topics include the efficacy and safety of both alirocumab and evolocumab in reducing lipids and CV events, survival and outcomes following bioprosthetic vs. mechanical mitral valve replacement, and more.
August 31st, 2014
Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. But the analysis, the authors cautioned, is a post-hoc analysis of a trial neither designed nor […]